about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Bios­plice, a for­mer an­ti-ag­ing uni­corn, slash­es staff in lat­est episode of its long fall from grace

4 years ago
People

Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

4 years ago
R&D

Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

4 years ago
Deals
R&D

An­oth­er mi­cro­cap biotech plots ma­jor job cuts as in­dus­try sharp­ens its axe amid slow­down

4 years ago
People
R&D

As­traZeneca dumps off a mid-stage PAD hope­ful, sound­ing re­treat from a packed mar­ket

4 years ago
Deals
R&D

Am­gen, look­ing for a path in­to red-hot 'mol­e­c­u­lar glues,' inks a deal with Plex­i­um for 2 pro­grams, po­ten­tial­ly more

4 years ago
Deals

A faster 'pro­tein print­er' out of the UK earns new round of fund­ing with plans to ex­pand plat­form

4 years ago
Financing
Discovery

FDA slams clin­i­cal hold on Log­icBio's gene edit­ing drug af­ter clot­ting cas­es in child pa­tients

4 years ago
Cell/Gene Tx
FDA+

Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in ...

4 years ago
News Briefing

Re­cent­ly stung by AAV, Sarep­ta dives a lit­tle deep­er in­to non-vi­ral de­liv­ery with newest li­cens­ing pact

4 years ago
Deals
Cell/Gene Tx

Biotech's very bad start to the year con­tin­ues as mi­cro­cap gene ther­a­py play­er Sio ditch­es CEO, lead part­ner­ship

4 years ago
People
R&D

As sirens blare on biotech pub­lic mar­kets, small cell ther­a­py play­er Gami­da plans to axe 10% of staff

4 years ago
People

A new Third Rock start­up seeks a 'sec­ond gold­en age' of GPCR drug dis­cov­ery based on No­bel lau­re­ate's work

4 years ago
Financing
Startups

Cy­to­Dyn fires em­bat­tled CEO as its grow­ing cho­rus of crit­ics gets loud­er

4 years ago
People

Mi­cro­cap can­cer play­er goes bel­ly up af­ter pan­cre­at­ic tu­mor hope­ful flops key study

4 years ago
R&D

EQRx adds ar­mor to its dis­count check­point in­hibitor sub­mis­sion, nail­ing sur­vival mark in key study

4 years ago
R&D

#JPM22: High­lights for the year ahead in on­col­o­gy R&D — What's hot, what's not?

4 years ago
R&D

De­nal­i's Alzheimer's drug faces set­back at the FDA af­ter agency slaps clin­i­cal hold on hu­man tri­al start

4 years ago
R&D

Bris­tol My­ers takes a swing at 'off-the-shelf' cell ther­a­pies in $150M cash li­cens­ing pact with Cen­tu­ry

4 years ago
Deals
Cell/Gene Tx

Pfiz­er, the new mas­ter of mR­NA de­liv­ery, teams up with Beam to ship base ed­i­tors straight to tar­get tis­sues

4 years ago
Deals
Cell/Gene Tx

Bay­er jumps on board Mam­moth­'s ul­tra-small CRISPR tech with sights set first on the liv­er

4 years ago
Deals
Cell/Gene Tx

A new start­up thinks it's found a key to drug­ging 'dis­or­dered' pro­teins — and it has plen­ty of cash to get start­ed

4 years ago
Financing
Startups

Re­gen­eron hands off ex-US rights for cho­les­terol dis­or­der drug to rare dis­ease spe­cial­ist Ul­tragenyx

4 years ago
Deals

Sanofi, Ex­sci­en­tia ink the next AI megadeal, sign­ing terms on a $100M up­front pact with up to 15 drugs on the line

4 years ago
Deals
R&D
First page Previous page 12345 Next page Last page
A service from the Financial Times